TissueTech has appointed Ted Davis as the company’s new president and CEO. Mr. Davis, a seasoned biologics and orthopedics executive, succeeds TissueTech founder and former CEO Amy Tseng, who retired on January 3. Ms. Tseng is still on the board of directors of the corporation.
“It is an honor to be only the second CEO in TissueTech’s 25-year history. I have watched the company for more than a decade and have been impressed with its platform technology, clinical outcomes, and surgeon support,” said Mr. Davis.
“With the addition of ongoing clinical programs to secure biologics license applications for indications to address significant unmet clinical needs in the ophthalmology, orthopedics, and wound management segments, TissueTech is poised to secure its position as a leader in regenerative medicine—now and into the future.”
Mr. Davis most recently served for 5 years as president and CEO of Active Implants LLC, a medical device company focused on the knee preservation segment of sports medicine.
He began his career as a venture capitalist in the health sciences industry, then moved into operational leadership roles at Wright Medical Technology and MicroPort Orthopedics before joining Active Implants, where he is currently a board member.
Mr. Davis is also a member of the boards of directors of Axis Spine Technologies and SIbone, Inc.
TissueTech has been a leader in the clinical application of human placental tissues since its founding in 1997. TissueTech products have now been used to treat over 600,000 patients, and the company's scientific and clinical successes have been recorded in over 300 peer-reviewed papers.